Journal
MOLECULES
Volume 27, Issue 13, Pages -Publisher
MDPI
DOI: 10.3390/molecules27134269
Keywords
antithrombotic agents; N,N '-malonamides; fXa inhibitors; thrombin inhibitors; acetylcholinesterase; butyrylcholinesterase; Alzheimer's disease
Funding
- Italian Ministry of Education, Universities (PRIN) [201744BN5T_004]
Ask authors/readers for more resources
This study explores the impact of the malonamide bridge on the enzyme inhibition potency of peptidomimetic inhibitors of coagulation factor Xa (fXa). Through the synthesis and testing of 23 malonamide derivatives, it was found that the malonamide linker significantly increases the anti-fXa potency and selectivity. Some of these compounds also show potential as neuroprotective agents for the treatment of Alzheimer's disease.
The rational discovery of new peptidomimetic inhibitors of the coagulation factor Xa (fXa) could help set more effective therapeutic options (to prevent atrial fibrillation). In this respect, we explored the conformational impact on the enzyme inhibition potency of the malonamide bridge, compared to the glycinamide one, as a linker connecting the P1 benzamidine anchoring moiety to the P4 aryl group of novel selective fXa inhibitors. We carried out structure-activity relationship (SAR) studies aimed at investigating Para- or meta-benzamidine as the P1 basic group as well as diversely decorated aryl moieties as P4 fragments. To this end, twenty-three malonamide derivatives were synthesized and tested as inhibitors of fXa and thrombin (thr); the molecular determinants behind potency and selectivity were also studied by employing molecular docking. The malonamide linker, compared to the glycinamide one, does significantly increase anti-fXa potency and selectivity. The meta-benzamidine (P1) derivatives bearing 2',4'-difluoro-biphenyl as the P4 moiety proved to be highly potent reversible fXa-selective inhibitors, achieving inhibition constants (K-i) in the low nanomolar range. The most active compounds were also tested against cholinesterase (ChE) isoforms (acetyl- or butyrylcholinesterase, AChE, and BChE), and some of them returned single-digit micromolar inhibition potency against AChE and/or BChE, both being drug targets for symptomatic treatment of mild-to-moderate Alzheimer's disease. Compounds 19h and 22b were selected as selective fXa inhibitors with potential as multimodal neuroprotective agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available